Form 4: BioCryst Executive's Tax-Related Stock Withholding
Insider Transaction Report
BioCryst Pharmaceuticals' President and CCO, Charles K Gayer, had 8,181 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.
Summary
- Charles K Gayer, President and CCO of BIOCRYST PHARMACEUTICALS INC (BCRX), reported a transaction on December 12, 2025.
- The transaction involved the disposition of 8,181 shares of Common Stock at a price of $7.57 per share.
- These shares were withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units.
- This transaction does not represent a sale by the reporting person.
- Following this transaction, Charles K Gayer beneficially owns 418,827 shares of Common Stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary insider transaction (shares withheld for tax obligations) which is neutral in sentiment and does not reflect positively or negatively on the company's performance or outlook.
Future Outlook
N/A. This filing is a historical report of an insider transaction and does not contain forward-looking statements or guidance.
Industry Context
N/A. This Form 4 filing reports a routine, non-discretionary insider transaction related to compensation and tax obligations, which is common across all publicly traded companies and does not provide specific insights into broader industry trends or competitive landscape.
Comparison to Industry Standards
- N/A. This filing details a standard tax withholding event for executive compensation, which is a common practice across industries and does not lend itself to a comparative assessment against specific industry benchmarks or competitor results.
Stakeholder Impact
- Shareholders: Minimal impact, as this is a routine, non-discretionary transaction related to executive compensation and tax obligations, not a discretionary sale or purchase indicating a change in management's view of the company.
- Employees: No direct impact beyond the reporting person.
Key Dates
| Date | Description |
|---|---|
| 12/12/2025 | Date of earliest transaction (shares withheld for tax) |
| 12/16/2025 | Signature date of the reporting person's power of attorney |
Keywords
BioCryst Pharmaceuticals, BCRX, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Obligations, Charles K Gayer, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.